Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-02 |
2024-03 |
-0.21 |
-0.23 |
-0.02 |
-9.52% |
2024-03-06 |
2023-12 |
-0.21 |
N/A |
N/A |
N/A |
2024-03-06 |
2023-12 |
-0.21 |
-0.19 |
0.02 |
9.52% |
2023-11-02 |
2023-09 |
-0.34 |
-0.25 |
0.09 |
26.47% |
2023-11-02 |
2023-09 |
-0.34 |
N/A |
N/A |
N/A |
2023-08-03 |
2023-06 |
-0.28 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-28 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-06-04 |
Wedbush |
Upgrade |
Outperform |
Outperform |
2023-05-29 |
SVB Securities |
Upgrade |
Market Perform |
Outperform |
2023-03-09 |
Wedbush |
Upgrade |
|
Outperform |
2023-01-08 |
SVB Leerink |
Upgrade |
|
Market Perform |
2022-11-09 |
JP Morgan |
Downgrade |
Neutral |
Underweight |
Date |
Name |
Relation |
Quantity |
Description |
2021-06-28 |
AISLING CAPITAL IV, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-08-31 |
CLACKSON TIMOTHY P |
Director |
47.33K |
Stock Gift |
2021-06-28 |
CORMORANT ASSET MANAGEMENT ,L.P |
Former |
0.00 |
Purchase |
2024-03-14 |
FERRA JOSEPH J. JR. |
Chief Executive Officer |
85.68K |
Conversion of Exercise of derivative security |
2024-02-14 |
FURLONG TAMMY CPA |
Chief Financial Officer |
797.00 |
Conversion of Exercise of derivative security |
2021-06-28 |
QIMING U.S. HEALTHCARE FUND II, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Tang Capital Management, LLC |
4.00M |
6.08M |
9.44% |
2023-06-29 |
venBio Partners LLC |
2.91M |
4.43M |
6.88% |
2023-06-29 |
Aisling Capital Management LP |
2.83M |
4.31M |
6.69% |
2023-06-29 |
Armistice Capital, LLC |
2.40M |
3.64M |
5.65% |
2023-06-29 |
Qiming U.s. Ventures Management, Llc |
2.37M |
3.60M |
5.59% |
2023-06-29 |
Millennium Management Llc |
2.32M |
3.52M |
5.47% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
854.85K |
1.30M |
2.02% |
2023-06-29 |
Vanguard Extended Market Index Fund |
201.74K |
306.64K |
0.48% |
2023-05-30 |
Fidelity Extended Market Index Fund |
67.27K |
283.87K |
0.16% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
50.00K |
76.00K |
0.12% |
2023-08-30 |
iShares Micro Cap ETF |
36.44K |
27.84K |
0.09% |
2023-05-30 |
Fidelity Total Market Index Fund |
23.93K |
100.98K |
0.06% |